Amarantus Reports Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease

Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS) announced the issuance of  Chinese patent number ZL2009801163060 entitled “Neurodegenerative Disorders” covering the use of MANF for the treatment of Parkinson’s disease and other neurodegenerative conditions.
According to the company press release:

The key claim issued in this patent is “Use of MANF for the manufacture of a medicament for administration to the substantia nigra region of the brain for treating Parkinson’s disease.” The substantia nigra is a key area of the brain where dopamine producing neurons degenerate in Parkinson’s disease. Additional claims covering combinations of MANF and other therapeutic moieties were also granted. This patent adds to Amarantus’ extensive international intellectual property portfolio covering compositions of matter, methods of use and formulations for MANF.

Gerald E. Commissiong, President & CEO of Amarantus.

The Chinese market represents a potential significant market opportunity for Amarantus. MANF has demonstrated proof of concept in various efficacy and delivery animal models of Parkinson’s disease. Going forward, the Company will look to partner the development of MANF with a group in China capable of bringing this technology to market in that region.

Click here to view the full press release.